ProCE Banner Activity

AURA: AZD9291 Active and Safe in Untreated EGFR Mutation–Positive Advanced NSCLC

Slideset Download
Conference Coverage
AZD9291, a third-generation irreversible EGFR tyrosine kinase inhibitor, demonstrated an ORR of 73% with few grade ≥ 3 adverse events in previously untreated patients with EGFR mutation–positive, advanced NSCLC.

Released: June 01, 2015

Expiration: May 30, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation